BCL2 and B-cell chronic lymphocytic leukemia: For example, whereas both CLL and DLBCL overexpress Bcl-2 protein (10, 22), the overall response rate (ORR) of patients to venetoclax-monotherapy strongly diverged with 79 and 18%, respectively.